Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination

Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine 1 , 2 , European health authorities recommended that patients under the age of 55 years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of the Pfizer BNT162b2 vaccine as a booster. However, the effective...

Full description

Saved in:
Bibliographic Details
Published in:Nature (London) 2021-12, Vol.600 (7890), p.701-706
Main Authors: Pozzetto, Bruno, Legros, Vincent, Djebali, Sophia, Barateau, Véronique, Guibert, Nicolas, Villard, Marine, Peyrot, Loïc, Allatif, Omran, Fassier, Jean-Baptiste, Massardier-Pilonchéry, Amélie, Brengel-Pesce, Karen, Yaugel-Novoa, Melyssa, Denolly, Solène, Boson, Bertrand, Bourlet, Thomas, Bal, Antonin, Valette, Martine, Andrieu, Thibault, Lina, Bruno, Cosset, François-Loïc, Paul, Stéphane, Defrance, Thierry, Marvel, Jacqueline, Walzer, Thierry, Trouillet-Assant, Sophie
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!